Synthesis of Hexahydrocyclopentimidazol-2-(1H)-one derivatives displaying selective DP-Receptor agonist properties

Bioorganic and Medicinal Chemistry

Volumn 4, Issue 1, 1996, Pages 81-90

  Barraclough, Paul ^a   Bolofo, Mary L ^a   Giles, Heather ^a   Gillam, Janet ^a   Harris, C John ^a   Kelly, Michael G ^a   Leff, Paul ^a   McNeill, Alan ^a   Robertson, Alan D ^a   Stepney, Ray J ^a   Whittle, Brendan J R ^a  

^a WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; BW 480C85; BW 572C85; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; YBW 587C;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; RABBIT; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; VASODILATATION;

EID: 0029968691     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/0968-0896(95)00173-5     Document Type: Article

References (33)

1. Miller, O. V.; Gorman, R. R. J. Pharmacol. Exp. Ther. 1979, 210, 134.
2. Coleman, R. A.; Humphrey, P. P. A.; Kennedy, I.; Lumley, P. Trends Pharmacol. Sci. 1984, 5, 303.
3. Data, J. L.; Molony, B. A.; Meinzinger, M. M.; Gorman, R. R. Circulation 1981, 64, 4.
4. Orchard, M. A.; Ritter, J. M.; Shepherd, G. L.; Lewis, P. J. Br. J. Clin. Pharmacol. 1983, 15, 509.
5. Whittle, B. J. R.; Moncada, S.; Vane, J. R. Prostaglandins 1978, 16, 373.
6. Town, M.-H.; Casals-Stenzel, J.; Schillinger, E. Prostaglandins 1983, 25, 13.
7. Giles, H.; Leff, P.; Bolofo, M. L.; Kelly, M. G.; Robertson, A. D. Br. J. Pharmacol. 1989, 96, 291.
8. Barraclough, P.; Jackson, W. P.; Harris, C. J. Arch. Pharm. (Weinheim) 1991, 324, 473.
9. Barraclough, P.; Caldwell, A. G.; Glen, R. C.; Harris, C. J.; Stepney, R. J.; Whittaker, N.; Whittle, B. J. R. Arch. Pharm. (Weinheim) 1993, 326, 85.
10. Barraclough, P.; Brockwell, M.; Caldwell, A. G.; Demaine, D. A.; Harris, C. J.; King, W. R.; Stepney, R. J.; Wharton, C. J.; Whittle, B. J. R. Arch. Pharm. (Weinheim) 1994, 327, 307.
11. Langs, D. A.; Erman, M.; DeTitta, G. T. Science 1977, 797, 1003.
12. Edmonds, J. W.; Duax, W. L. Prostaglandins 1974, 5, 275.
13. Andersen, N. H.; Lin, B.-S. Biochemistry 1985, 24, 2338.
14. Tsai, A.-L.; Strobel-Jager, E.; Wu, K. K. J. Comp. Aid. Mol. Design 1991, 5, 135.
15. DePuy, C. H.; Ponder, B. W.; Fitzpatrick, J. D. J. Org. Chem. 1964, 29, 3508.
16. Zhou, Z.-L.; Shi, L.-L.; Huang, Y.-Z. J. Chem. Soc., Perkin Trans. 1 1991, 1931.
17. Kaiser, E. M.; Hauser, C. R. J. Org. Chem. 1968, 33, 3402.
18. fs of 18 and 19 are 0.3 and 0.2 (silica, ethyl acetate : methanol, 9:1) respectively.
19. 6a=8.8 Hz.
20. matrix presented
21. De Gregori, A.; Jommi, G.; Sisti, M.; Gariboldi, P.; Merati, F. Tetrahedron 1988, 44, 2549.
22. 3a,6a=8.8Hz.
23. Sakai, K.; Anselme, J.-P. Org. Prep. Proced. Int. 1975, 7, 61.
24. 1H NMR spectra of 31 and 33 were analysed in detail as before and the chemical shifts and coupling constants of the cyclopentane ring protons were similar to those of 35 and 7, respectively.
25. fs of 31 and 32 are 0.3 and 0.2 (silica, ethyl acetate : methanol, 19:1).
26. Some preliminary experimental details for Scheme 2 are given in Eur. Pat. Appl. 458 642 (Chem. Abstr. 1992, 116; 106293b).
27. Some preliminary experimental details for Scheme 1 are given in Eur. Pat. Appl. 46 597 (Chem. Abstr. 1982, 97; 144568w).
28. Whittle, B. J. R.; Moncada, S.; Mullane, K.; Vane, J. R. Prostaglandins 1983, 25, 205.
29. Leff, P.; Giles, H. Br. J. Pharmacol. 1992, 106, 996.
30. 2, reflux and purification by the methyl ester). Attempts to obtain 39 by a similar route have so far proved unsuccessful. Preliminary evaluation of 38 indicate it is a weak non-selective DP-agonist.
31. matrix presented
32. Ross, W. J.; Harrison, R. G.; Jolley, M. R. J.; Neville, M. C.; Todd, A.; Verge, J. P. J. Med. Chem. 1979, 22, 412.
33. Dong, Y. J.; Jones, R. L.; Wilson, N. H. Br. J. Pharmacol. 1986, 87, 97.